$DRUG News

HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

HC Wainwright & Co. Maintains Buy on Bright Minds Biosciences, Raises Price Target to $145

Bright Minds Biosciences to Present at Upcoming Conferences

Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials

Canadian Securities Exchange Reports January 2026 Performance Figures

BTIG Maintains Buy on Bright Minds Biosciences, Maintains $147 Price Target

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Prices $175M Offering Of 1,945,000 Common Shares At $90/Share

Reported Earlier, Bright Minds Biosciences Prices Upsized $175.05M Public Offering Of 1.945M Common Shares At $90.00 Per Share

Reported Earlier, Bright Minds Biosciences Prices Upsized $175.05M Public Offering Of 1.945M Common Shares At $90.00 Per Share

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

BTIG Maintains Buy on Bright Minds Biosciences, Raises Price Target to $147

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Bright Minds Biosciences Announces Launch Of $100M Public Offering